*VIVENDI TO BUY ORANGE'S DAILYMOTION, LE FIGARO SAYS

+------------------------------------------------------------------------------+

BN 04/06 14:22 *VIVENDI MAY PAY MORE THAN EU250 MLN FOR DAILYMOTION: FIGARO

+------------------------------------------------------------------------------+

*VIVENDI TO BUY ORANGE'S DAILYMOTION, LE FIGARO SAYS 2015-04-06 14:21:59.233 GMT

--JIM SILVER

-0- Apr/06/2015 14:21 GMT

>>> RIO US +0.45% in pre-market --> could move on this FT Article have a look

Glencore’s Glasenberg bides his time on Rio Tinto

Ivan Glasenberg is not a chief executive short of opinions. But for the past six months, he has been uncharacteristically silent on one topic.
In October, Glencore, the company he leads, revealed that an informal merger approach to its larger rival, Rio Tinto, had been rebuffed some months earlier.
Under the provisions of UK takeover law, the revelation started an important clock ticking: Glencore was barred from further discussing the Anglo-Australian mining group for a full six months — a period that expires next week.
Will Glencore return with another approach to Rio? A combination of the second and largest miners by market value would create a $130bn resources group with an unprecedentedly broad exposure to a range of raw materials.
It would also be a decisive way to try to fight the gloom in commodity markets, where prices continue to soften amid concerns about slowing growth in China. But six months on, there are few reasons to think Rio shareholders would be interested in merging with a smaller rival. “Glencore still needs Rio more than the other way around,” said Ben Davis, analyst at Liberum.
It was immediately clear in the aftermath of October’s revelations that, for Glencore to pull off a deal, many stars would have to align. So far that has not happened. While the price of iron ore, the source of about 80 per cent of Rio’s earnings last year, has slumped to its lowest level in decade, the company has managed to increase its dividend, launch a share buyback and cut its debt.

This has helped support Rio’s share price and means that Glencore is no closer to solving the main obstacle to any deal: the fact that Rio remains a bigger company.
“The likelihood of a deal being announced in the near term remains unlikely,” said Jeff Largey of Macquarie Bank in London.
When Mr Glasenberg called Rio chairman Jan du Plessis to pitch the merger idea, the Glencore/Rio share ratio was around 9:1, that is, the price of a Rio share was equal to about nine of Glencore’s. That widened to 12:1 in January as the price of copper, Glencore’s most important commodity, slumped. It is now just under 10:1.
“We still wouldn’t even expect the possibility of a bid till the share ratio gets to below 8:1. Even then I don’t see where there is a sweet spot that gives enough premium for Rio shareholders and is not too dilutive to Glencore shareholders,” said Mr Davis.
Institutional investors are largely content with the job Sam Walsh, Rio’s chief executive, has done in pruning costs and cutting spending, even if some have reservations about his strategy of pumping more iron ore into the market, in an effort to keep market share and drive higher-cost producers out of business.
“Mr Walsh has shown that he can and will cut costs,” said Michael Hulme of Carmignac Gestion, a fund manager.

The relatively weak performance, which analysts attribute to Glencore’s debt levels, is not the only reason a fresh approach looks unlikely. Glencore’s triple B credit rating could be in jeopardy if it attempts a major deal this year.
Furthermore, Rio remains resolutely opposed to a combination of the two businesses. Mr Walsh told an audience at Chatham House in February that even if Glencore could come up with an offer that was attractive for Rio shareholders, a merger would never happen because it would not clear regulatory hurdles.
“The interesting thing is that, the media are sort of infatuated with this, and I guess it’s because it sells newspapers or gets people watching TV or what have you. But as I move around investors, investors say: ‘I don’t get it. Why are you giving this any ear? Because it actually isn’t going to happen’,” he said.
But for Mr Glasenberg, the attractions of a deal remain. Not only would it create the world’s biggest resources company but Glencore would get access to Rio’s balance sheet and its Australian iron ore assets, widely acknowledged to be the best in the industry.
Yet the steelmaking ingredient, which plunged 50 per cent in 2014, has extended its losses this year on concerns about a supply glut and currently iron ore languishes below $50 a tonne.
It means Mr Glasenberg’s best option is to remain patient.
“Glencore is content to let the iron ore price continue to fall and put further pressure on iron ore miners,” says Mr Largey. “Rio’s balance sheet remains solid but further weakness in iron ore prices will weigh on its valuation and affect the way investors feel about the company.”

>>> US Gapping up

Gapping up
In reaction to strong earnings/guidance
: CFRX +4.6%

M&A news: GAME +6.6% (enters into definitive merger agreement for going private transaction at $7.10 per ADS), SNE +4.1% (will acquire some parts of OnLive), GG +3.2% (announces sale of its interest in the South Arturo Mine Project), VTR +1.7% (signed a definitive agreement to acquire privately-owned Ardent Medical Services for $1.75 bln in cash; also announces plan to spin off post-acute/skilled nursing facility portfolio)

Select metals/mining stocks trading higher: AUY +4%, KGC +3.9%, AEM +3.6%, GDX +3.2%, EGO +3.1%, ABX +3.1%, SLW +3.1%, NEM +3.1%, PAAS +2.9%, AU +2.8%, IAG +2.5%, HL +2.2%, SLV +2.1%, GLD +1.5%, FCX +1.2%

Other news: QURE +57.2% (and Bristol-Myers Squibb enter into exclusive strategic collaboration to develop gene therapies for cardiovascular diseases), CYTX +25% (announces its exclusive licensee, Lorem Vascular, has been granted regulatory clearance for the Cytori Celution System by the State FDA of the People's Republic of China), TCPI +12.8% (cont strength),CRIS +9.4% (granted orphan designation status by the FDA for C24H28N8O7S2 for the treatment of diffuse large B-cell lymphoma), CAPN +7.4% (awarded a Small Business Innovation Research Phase I grant totaling ~$220k by the National Heart, Lung, and Blood Institute, a division of the National Institutes of Health), BIOD +5.9% (announces results from a formative human factors study of its Glucagon Emergency Management device for the treatment of diabetes patients experiencing severe hypoglycemi), NBG +4.1% (opitimism in Greece with its Fin Min to meet with IMF), TSLA +3.8% (announces it delivered 10,030 cars in Q1 of 2015, a new record and 55% increase YoY), ARIA +3.1% (announces approval of iclusig in Canada),NNVC +2.7% (provides update on progress over the last quarter), SHPG +1% (comments on USPTO petitions related to LIALDA and GATTEX; will continue to defend vigorously its patents and pursue all legal options available to protect its products)

Analyst comments: LL +2.1% (upgraded to Outperform from Mkt Perform at Raymond James), SCMP +2% (initiated with a Buy at Guggenheim), RAD +1.6% (resumed with a Overweight at JP Morgan), ENTA +1.5% (initiated with a Buy at Deutsche Bank), VMW +1.4% (upgraded to Buy from Neutral at Nomura), SPLK +1.2% (upgraded to Overweight from Equal Weight at a boutique firm), BRCM +1% (added to FBR Top Picks List)

>>> US Gapping down

Gapping down
In reaction to disappointing earnings/guidance
: ICE -0.7%, (monthy volume data)

Select Airline related names showing weakness: LUV -1.4%, DAL -1.3%, JBLU -1.2%, HA -1%, ALK -0.9%

Other news: RESN -40.9% (annouced the development agreement with its first customer has been terminated), DGLY -6.9% (stock traded 10% higher on Thursday after co tweeted about an upcoming 'big announcement' ... PGA sponsorship was announced but seems to have disappointed some momentum investors), WBAI -6.3% (issues public announcement regarding online lottery sales in China), HLF -5.8% (reports that Federal law agencies last week contacted HLF members about business practices), NYMX -2.9% (pulling back pre-mkt following last week's strong run), NXPI -1.4% (still checking), O -1.4% (has commenced an underwritten public offering of 5 mln shares of common stock), YELP -1.3% (ChowNow announced a new partnership with Google (GOOG); seen as increased competition to YELP)

Analyst comments: MHR -8.9% (downgraded to Hold at Wunderlich), GRMN -3.2% (downgraded to Sell from Buy at Citigroup), QCOM -2.3% (downgraded to Mkt Perform from Outperform at FBR Capital), RF -2.1% (downgraded to Neutral from Buy at Guggenheim), WU -2.1% (downgraded to Neutral from Positive at Susquehanna), GCI -1.8% (downgraded to Mkt Perform from Outperform at FBR Capital), SWKS -1.8% (downgraded to Equal Weight from Overweight at a boutique firm), TRIP -1.8% (downgraded to Hold from Buy at Needham), AGCO -1.4% (downgraded to Sell from Hold at Deutsche Bank)

>>> EBAY/AMZN - Reportedly more merchants are moving business from eBay to Amazo

Reportedly more merchants are moving business from eBay to Amazon.com - financial press 
- Amazons pool of merchants doubled to about 2 million in 2014, while the number of sellers on EBay has remained flat at 25 million in the past two years.
- Many sellers say Amazon is worth the extra expense to achieve greater sales volumes and that its cheaper to let Amazon handle logistics than do it themselves.
- Amazon, which has 270 million active buyers compared with EBays 155 million, has had a third-party marketplace since 2000 and started offering Fulfillment by Amazon in 2007. Some sellers have been wary of Amazon, since it can also be a retail competitor.
{NSN NM7C646VDKHW<Go>}

>>> Emerson (EMR US) - Reports Feb trailing 3-month orders -5% to flat

--> read across for Europe Schneider, Legrand, ABB, Siemens, ...


Reports Feb trailing 3-month orders -5% to flat 

Trailing three-month orders decreased 10 percentage points, reflecting the dramatic drop in oil prices, mixed demand among geographies and markets, and significant strength in the U.S. dollar, which deducted 7 percentage points through currency translation. These economic conditions are having a more significant impact on order rates than previously expected. Underlying orders were down low-single-digits, reflecting modest growth in Commercial & Residential Solutions, flat orders in Process Management, and decreases in other segments. The February orders release is later than the customary timing as the Company sought to gain better visibility into March orders and sales. We now expect second quarter underlying sales to be approximately flat compared with prior year, which excludes unfavorable currency translation of 5 percent and an impact from divestitures of 2 percent. Reported GAAP sales for the second quarter are expected to be down approximately 7 percent.

* Process Management orders trends continued to reflect unfavorable currency translation, which deducted 11 percentage points, including backlog revaluation. Underlying orders were flat, with growth in Europe (including a large power project in Poland) and North America offset by decreases in other world areas. Downstream activity continues to be a positive, particularly in the chemical/petrochemical and power industries.

* Industrial Automation orders were down, reflecting weakness in Europe and unfavorable currency. Underlying orders were down, as continued weakness in power generation and motors and drives more than offset growth in the materials joining and fluid automation businesses. Currency translation deducted 6 percentage points.

* Network Power orders decreased as underlying demand for telecommunications and data center infrastructure investment remained weak. Asia experienced modest growth, but was more than offset by decreases in the Americas and Europe. Currency translation deducted 5 percentage points.

* Climate Technologies orders were down as U.S. HVAC customers continue to work through pre-built inventory driven by regulatory changes for U.S. residential air conditioning. Underlying orders were down low-single-digits, with strong growth in Asia offset by decreases in North America and Europe. Orders in the commercial and industrial refrigeration business remained strong. Currency translation deducted 3 percentage points.

* Commercial & Residential Solutions orders grew modestly, reflecting favorable trends in U.S. residential and commercial construction. Growth was led by the food waste disposers, and storage businesses. Currency translation deducted 2 percentage points. - Source TradeTheNews.com

>>> JNJ - FDA Files Supplemental New Drug Application for Boehringer Ingelheim's

FDA Files Supplemental New Drug Application for Boehringer Ingelheim's Pradaxa® (dabigatran etexilate mesylate) for the Prophylaxis of Deep Venous Thrombosis and Pulmonary Embolism After Hip Replacement Surgery Announced that the U.S. Food and Drug Administration (FDA) filed a supplemental New Drug Application (sNDA) for Pradaxa(dabigatran etexilate mesylate) for the prophylaxis of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients who have had primary elective total hip replacement surgery. If approved, this will become the fourth indication for PRADAXA.

The submission to the FDA is based on the results of two randomized, double-blind, phase III trials, RE-NOVATEand RE-NOVATEII. The studies compared the efficacy and safety of PRADAXA to enoxaparin in preventing venous thromboembolism (VTE) and death in patients undergoing total hip replacement surgery.

In RE-NOVATE, 3,494 patients having primary elective total hip replacement were randomized to three groups receiving prophylactic treatment with one of two doses of PRADAXA (220 mg or 150 mg) once daily or enoxaparin 40 mg once daily for 28 to 35 days. The first PRADAXA group was given a dose of 110 mg on the day of surgery and 220 mg daily thereafter; the second PRADAXA group received a dose of 75 mg on the day of surgery and 150 mg daily thereafter. The enoxaparin group was given a dose of 40 mg the day before surgery and daily thereafter.